Intraperitoneal treatment for peritoneal mucinous carcinomatosis of appendiceal origin after operative management: Long-term follow-up of the mayo clinic experience

Annals of Surgery

Volumn 249, Issue 4, 2009, Pages 588-595

  Schomas, David A ^a   Miller, Robert C ^a   Donohue, John H ^a   Gill, Sharlene ^b   Thurmes, Paul J ^c   Haddock, Michael G ^a   Quevedo, J Fernando ^a   Gunderson, Leonard L ^d  

^a MAYO CLINIC   (United States)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c MAYO CLINIC   (United States)

^d Minnesota Oncology and Hematology Professional Association   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMIUM PHOSPHATE P 32; FLUOROURACIL; RADIOISOTOPE; 1 ETHYL 2,3 DIOXOPIPERAZINE; 1-ETHYL-2,3-DIOXOPIPERAZINE; PIPERAZINE DERIVATIVE;

ADULT; AGED; APPENDIX TUMOR; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CYTOREDUCTIVE SURGERY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; ANALYSIS OF VARIANCE; APPENDECTOMY; CANCER CENTER; CANCER STAGING; COHORT ANALYSIS; COLLOID CARCINOMA; INFUSION; KAPLAN MEIER METHOD; METASTASIS; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; NONPARAMETRIC TEST; PATHOLOGY; PERITONEUM TUMOR; PROBABILITY; PROPORTIONAL HAZARDS MODEL; REGIONAL PERFUSION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL; TIME; UNITED STATES;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; APPENDECTOMY; APPENDICEAL NEOPLASMS; CANCER CARE FACILITIES; CHEMOTHERAPY, ADJUVANT; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, PARENTERAL; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MINNESOTA; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PERITONEAL NEOPLASMS; PIPERAZINES; PROBABILITY; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 65449172061     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e31819ec7e3     Document Type: Article

References (70)

1. Hinson FL, Ambrose NS. Pseudomyxoma peritonei. Br J Surg. 1998;85: 1332-1339.
2. Smith JW, Kemeny N, Caldwell C, et al. Pseudomyxoma peritonei of appendiceal origin: the Memorial Sloan-Kettering Cancer Center experience. Cancer. 1992;70:396-401.
3. Sugarbaker PH, Ronnett BM, Archer A, et al. Pseudomyxoma peritonei syndrome. Adv Surg. 1996;30:233-280.
4. Carleton CC. Mucoceles of the appendix and peritoneal pseudomyxoma. AMA Arch Pathol. 1955;60:39-48.
5. Hughes J. Mucocele of the appendix with pseudomyxoma peritonei: a benign or malignant disease? Ann Surg. 1967;165:73-76.
6. Deraco M, Baratti D, Inglese MG, et al. Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): a strategy that has confirmed its efficacy in patients with pseudomyxoma peritonei. Ann Surg Oncol. 2004;11:393-398.
7. Ronnett BM, Yan H, Kurman RJ, et al. Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer. 2001;92:85-91.
8. Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol. 1999;6:727-731.
9. Stewart JH IV, Shen P, Russell GB, et al. Appendiceal neoplasms with peritoneal dissemination: outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy. Ann Surg Oncol. 2006;13:624-634.
10. Loungnarath R, Causeret S, Bossard N, et al. Cytoreductive surgery with intraperitoneal chemohyperthermia for the treatment of pseudomyxoma peritonei: a prospective study. Dis Colon Rectum. 2005;48:1372-1379.
11. Guner Z, Schmidt U, Dahlke MH, et al. Cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei. Int J Colorectal Dis. 2005;20:155-160.
12. Moran BJ, Meade B, Murphy E. Hyperthermic intraperitoneal chemotherapy and cytoreductive surgery for peritoneal carcinomatosis of colorectal origin: a novel treatment strategy with promising results in selected patients. Colorectal Dis. 2006;8:544-550.
13. Moran BJ, Mukherjee A, Sexton R. Operability and early outcome in 100 consecutive laparotomies for peritoneal malignancy. Br J Surg. 2006;93:100-104.
14. Gough DB, Donohue JH, Schutt AJ, et al. Pseudomyxoma peritonei: long-term patient survival with an aggressive regional approach. Ann Surg. 1994;219:112-119.
15. Wirtzfeld DA, Rodriguez-Bigas M, Weber T, et al. Disseminated peritoneal adenomucinosis: a critical review. Ann Surg Oncol. 1999;6:797-801.
16. Yan TD, Links M, Xu ZY, et al. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal mucinous neoplasms. Br J Surg. 2006;93:1270-1276.
17. Yan TD, Sugarbaker PH, Brun EA. Pseudomyxoma peritonei from mucinous adenocarcinoma of the urachus. J Clin Oncol. 2006;24:4944-4946.
18. Smeenk RM, Verwaal VJ, Antonini N, et al. Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg. 2007;245:104-109.
19. Sugarbaker PH, Kern K, Lack E. Malignant pseudomyxoma peritonei of colonic origin: natural history and presentation of a curative approach to treatment. Dis Colon Rectum. 1987;30:772-779.
20. Glehen O, Osinsky D, Beaujard AC, et al. Natural history of peritoneal carcinomatosis from nongynecologic malignancies. Surg Oncol Clin N Am. 2003;12:729-739.
21. Kusamura S, Younan R, Baratti D, et al. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer. 2006;106:1144-1153.
22. Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg. 1995;221:124-132.
23. Sugarbaker PH, Landy D, Jaffe G, et al. Histologic changes induced by intraperitoneal chemotherapy with 5-fluorouracil and mitomycin C in patients with peritoneal carcinomatosis from cystadenocarcinoma of the colon or appendix. Cancer. 1990;65:1495-1501.
24. Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol. 2006;7:69-76.
25. Novell R, Lewis A. Role of surgery in the treatment of pseudomyxoma peritonei. JR Coll Surg Edinb. 1990;35:21-24.
26. Mann WJ Jr, Wagner J, Chumas J, et al. The management of pseudomyxoma peritonei. Cancer. 1990;66:1636-1640.
27. Varona JF, Guerra JM, Salamanca J, et al. Pseudomyxoma peritonei: a clinicopathologic analysis and follow-up of 21 patients. Hepatogastroenterology. 2005;52:812-816.
28. Yan TD, Black D, Savady R, et al. A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol. 2007;14:484-492.
29. Carter J, Moradi MM, Elg S, et al. Pseudomyxoma peritonei: experience from a tertiary referral centre. Aust N Z J Obstet Gynaecol. 1991;31:177-178.
30. Long RT, Spratt JS Jr, Dowling E. Pseudomyxoma peritonei: new concepts in management with a report of seventeen patients. Am J Surg. 1969;117:162-169.
31. Bernhardt H, Young JM. Mucocele and pseudomyxoma peritonei of appendiceal origin: clinicopathologic aspects. Am J Surg. 1965;109:235-241.
32. Mohlen K, Beller FK. Pseudomyxoma peritonei: effect of radiogold therapy [in Germany]. Zentralbl Gynakol. 1978;100:1408-1411.
33. Laitinen JO, Kairemo KJ, Jekunen AP, et al. The effect of three-dimensional activity distribution on the dose planning of radioimmunotherapy for patients with advanced intraperitoneal pseudomyxoma. Cancer. 1997;80(suppl 12): 2545-2552.
34. Yan TD, Bijelic L, Sugarbaker PH. Critical analysis of treatment failure after complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from appendiceal mucinous neoplasms. Ann Surg Oncol. 2007;14:2289-2299.
35. Jacquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res. 1996;15:49-58.
36. Speyer JL. The rationale behind intraperitoneal chemotherapy in gastrointestinal malignancies. Semin Oncol. 1985;12(suppl 4):23-28.
37. Speyer JL, Collins JM, Dedrick RL, et al. Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally. Cancer Res. 1980;40: 567-572.
38. Speyer JL, Sugarbaker PH, Collins JM, et al. Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans. Cancer Res. 1981;41:1916-1922.
39. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
40. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II: analysis and examples. Br J Cancer. 1977;35:1-39.
41. Cox DR. Statistical significance tests. Br J Clin Pharmacol. 1982;14:325-331.
42. Werth R. Pseudomyxoma peritonei. Arch Gynecol Obstet. 1884;24:100-118.
43. Bender MD, Ockner RK. Diseases of the peritoneum, mesentery, and diaphragm. In: Sleisenger MH, Fordtran JS, eds. Gastrointestinal Disease: Pathophysiology, Diagnosis, Management. 3rd ed. Philadelphia, PA: Saun-ders; 1983:1569-1596.
44. Bouchier IAD, Pennington CR. Ascites. In: Bouchier IA, Allan RN, Hodgson HJF, et al, eds. Textbook of Gastroenterology. London: Bailliere Tindall; 1984:1477-1486.
45. Nance FC. Diseases of the peritoneum, mesentary, and omentum. In: Berk JE, ed. Bockus Gastroenterology. 4th ed. Philadelphia, PA: Saunders; 1985: 4177-4198.
46. Fernandez RN, Daly JM. Pseudomyxoma peritonei. Arch Surg. 1980;115: 409-414.
47. Kochhar R. Pseudomyxoma peritonei: benign or malignant. Gastroenterol-ogy. 1986;91:1320-1321.
48. Rotmensch J, Rosenshein N, Parmley T. Extraperitoneal extension of pseudomyxoma peritonei: a case report. Gynecol Oncol. 1982;13:101-107.
49. Jones CM III, Homesley HD. Successful treatment of pseudomyxoma peri-tonei of ovarian origin with cis-platinum, doxorubicin, and cyclophospha-mide. Gynecol Oncol. 1985;22:257-259.
50. Carmignani CP, Sugarbaker TA, Bromley CM, et al. Intraperitoneal cancer dissemination: mechanisms of the patterns of spread. Cancer Metastasis Rev. 2003;22:465-472.
51. Miner TJ, Shia J, Jaques DP, et al. Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy. Ann Surg. 2005; 241:300-308.
52. Smeenk RM, Verwaal VJ, Zoetmulder FA. Toxicity and mortality of cytore-duction and intraoperative hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei: a report of 103 procedures. Eur J Surg Oncol. 2006;32:186-190.
53. Cariker M, Dockerty M. Mucinous cystadenomas and mucinous cystadeno-carcinomas of the ovary: a clinical and pathological study of 355 cases. Cancer. 1954;7:302-310.
54. Bradley RF, Stewart JH IV, Russell GB, et al. Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review. Am J Surg Pathol. 2006;30:551-559.
55. Glehen O, Mithieux F, Osinsky D, et al. Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. J Clin Oncol. 2003;21: 799-806.
56. Sugarbaker PH. Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome. Eur J Surg Oncol. 2001;27:239-243.
57. Elias D, Laurent S, Antoun S, et al. Pseudomyxoma peritonei treated with complete resection and immediate intraperitoneal chemotherapy [in French]. Gastroenterol Clin Biol. 2003;27:407-412.
58. Sugarbaker PH, Zhu BW, Sese GB, et al. Peritoneal carcinomatosis from appendiceal cancer: results in 69 patients treated by cytoreductive surgery and intraperitoneal chemotherapy. Dis Colon Rectum. 1993;36:323-329.
59. van Ruth S, Acherman YI, van de Vijver MJ, et al. Pseudomyxoma peritonei: a review of 62 cases. Eur J Surg Oncol. 2003;29:682-688.
60. Gonzalez-Moreno S, Sugarbaker PH. Right hemicolectomy does not confer a survival advantage in patients with mucinous carcinoma of the appendix and peritoneal seeding. Br J Surg. 2004;91:304-311.
61. Butterworth SA, Panton ON, Klaassen DJ, et al. Morbidity and mortality associated with intraperitoneal chemotherapy for pseudomyxoma peritonei. Am J Surg. 2002;183:529-532.
62. Hopkins ML, Depetrillo AD, Le T, et al. Pseudomyxoma peritonei: a case series and review of the literature. Int J Gynecol Cancer. 2005;15:32-36.
63. Smeenk RM, Verwaal VJ, Antonini N, et al. Progression of pseudomyxoma peritonei after combined modality treatment: management and outcome. Ann Surg Oncol. 2007;14:493-499.
64. Wertheim I, Fleischhacker D, McLachlin CM, et al. Pseudomyxoma peritonei: a review of 23 cases. Obstet Gynecol. 1994;84:17-21.
65. Sugarbaker PH, Alderman R, Edwards G, et al. Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy. Ann Surg Oncol. 2006;13:635-644.
66. Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221:29-42.
67. Park JG, Kramer BS, Steinberg SM, et al. Chemosensitivity testing of human colorectal carcinoma cell lines using a tetrazolium-based colorimetric assay. Cancer Res. 1987;47:5875-5879.
68. Jol C, Kuppen P, Leefgang PA, et al. In vitro pharmacology of mitomycin-C in human ovarian cancer. In: Taguchi T, Andrysek O, eds. New trends in cancer chemotherapy with mitomycin-C. Amsterdam, Netherlands: Excerpta Medica; 1987:181-191.
69. Ohta Y, Shima Y, Sasaki N, et al. Successful treatment of pseudomyxoma peritonei using combination chemotherapy of intraperitoneal low-dose CDDP and oral 5'-DFUR administration [in Japanese]. Gan To Kagaku Ryoho. 1998;25:929-932.
70. Kusamura S, Deraco M, Baratti D, et al. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of peritoneal surface malignancies: morbidity and mortality with closed abdomen technique. J Exp Clin Cancer Res. 2003;22(suppl 4):207-212.